|
Daily Medical Update
Hepatocellular carcinoma
Thursday, May 07, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Journal of Gastroenterology and Hepatology (2026) - Systematic Review and Meta-Analysis
Key Findings
- Across 18 studies with 3478 patients, adjuvant ICI-based therapy improved recurrence-free survival versus surveillance (HR 0.51, 95% CI 0.44-0.60), with benefit seen for both ICI monotherapy and ICI plus TKI or anti-angiogenic combinations.
- Overall survival also favored adjuvant ICI-based treatment over surveillance (HR 0.51, 95% CI 0.40-0.65), and the recurrence-free survival benefit remained consistent after resection or ablation.
📋 Practice Implication: Patients at high risk of recurrence after resection or ablation should be considered for adjuvant ICI-based strategies where available, while clinicians watch for confirmatory phase III data.
|
Asian Pacific Journal of Cancer Prevention (2026) - Network Meta-Analysis
Key Findings
- In 11 studies of unresectable HCC, no statistically significant overall survival difference was found between atezolizumab plus bevacizumab and lenvatinib (HR 0.98, 95% CI 0.24-4.10), atezolizumab plus bevacizumab and sorafenib (HR 1.40, 95% CI 0.21-9.87), or lenvatinib and sorafenib (HR 1.41, 95% CI 0.38-5.14).
- Surface under the cumulative ranking curve analysis ranked atezolizumab plus bevacizumab first, but this did not translate into a statistically significant overall survival improvement versus lenvatinib or sorafenib.
📋 Practice Implication: First-line selection for unresectable HCC should still be individualized by comorbidity, bleeding risk, liver reserve, and access, because current comparative evidence suggests only a trend rather than a definitive survival winner.
|
Clinical Oncology (2026) - Systematic Review and Meta-Analysis
Key Findings
- In indirect comparisons versus non-ICI controls, immunotherapy benefit was strongest in HBV-related HCC (OS HR 0.67; PFS HR 0.58), intermediate in HCV-related HCC (OS HR 0.84; PFS HR 0.75), and most attenuated in nonviral HCC (OS HR 0.88; PFS HR 0.71).
- Among patients receiving ICIs, viral HCC had significantly better progression-free survival than nonviral HCC (HR 0.84) and showed a trend toward improved overall survival (HR 0.91).
📋 Practice Implication: Etiology should be incorporated into treatment counseling and trial stratification, with the strongest expectation of ICI benefit in HBV-associated disease and the most tempered expectations in nonviral HCC.
|
Frontiers in Immunology (2026) - Systematic Review and Meta-Analysis
Key Findings
- Across 19 cohort studies involving 3720 patients with advanced HCC, adding immunotherapy to locoregional therapy improved overall survival (HR 0.36) and progression-free survival (HR 0.41) compared with locoregional therapy alone.
- The combination approach also improved disease control rate (OR 2.17) and objective response rate (OR 1.85) but increased grade 3 or higher adverse events (OR 1.26), including higher risks of pneumonitis and myocarditis.
📋 Practice Implication: For advanced HCC being managed with TACE- or HAIC-based strategies, adding immunotherapy is a reasonable escalation when the team can monitor and manage immune-related toxicity.
|
International Journal of Clinical Oncology (2026) - Systematic Review and Meta-Analysis
Key Findings
- Across 17 studies, ICI-based regimens improved overall survival versus TKI monotherapy (HR 0.81, 95% CI 0.68-0.95) and progression-free survival (HR 0.76, 95% CI 0.64-0.91) in advanced HCC.
- ICI-based regimens also increased objective response rate (RR 1.59, 95% CI 1.11-2.28), with subgroup analyses showing treatment effects varied by HCC etiology and Child-Turcotte-Pugh class.
📋 Practice Implication: When systemic therapy is needed for advanced HCC, ICI-based regimens should generally be favored over TKI monotherapy, but the choice should still be adjusted to underlying etiology and hepatic functional reserve.
|
|
💡
Summary
Recent hepatocellular carcinoma evidence is dominated by immunotherapy-focused meta-analyses spanning adjuvant, advanced, and multimodality care. Adjuvant ICI-based therapy after curative treatment and ICI-based regimens for advanced disease were associated with better survival outcomes, while viral etiology consistently predicted greater benefit; in unresectable first-line comparisons, atezolizumab plus bevacizumab, lenvatinib, and sorafenib showed similar overall survival with only ranking trends favoring atezolizumab plus bevacizumab.
|
|